Highlife SAS, a Paris-based med-tech company focused on the development of a transcatheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, recently closed a €32 million (US$36.4 million) round of equity financing.
Medtronic plc, of Dublin, reported that the first patient has been enrolled in the Embrace targeted drug delivery (TDD) clinical study with the Synchromed II intrathecal drug delivery system. The prospective, multicenter, postmarket Embrace TDD study will enroll about 100 patients with chronic, intractable, nonmalignant primary back pain with or without leg pain at up to 15 sites in the U.S.
RSS